• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Third dose of ChAdOx1 nCoV-19 vaccine and prolonged second dose-intervals are both associated with increased antibody titers

byNeel MistryandTeddy Guo
September 21, 2021
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody titers, 28-days after administration, compared to the standard interval of 8-12 weeks.

2. A two-fold increase in median IgG levels was observed among patients 28-days after receiving their third dose compared to 28-days after the second.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The optimal interval of time between the first and second dose of COVID-19 vaccines has been a subject of debate. In addition, while countries facing supply shortages consider the impact of extending the dosing interval, those with a surplus mull over the possibility of a third booster dose. So far, little research has been done to assess the impact of either regimen on SARS-CoV-2 immunogenicity. This sub study of two randomized controlled trials aimed to assess the efficacy of a prolonged second dose of ChAdOx1 nCoV-19, compared to the regular 8-12-week interval. This study also sought to identify the response to a third dose given to patients 28-38 weeks after the second dose. The outcomes measured in this study were IgG-antibody titers levels 28-days after receipt of a second or third dose of ChAdOx1 nCoV-19. According to study results, an increase in immunogenicity was reported among patients with a prolonged second dose interval and among those who received an additional third dose. This study was limited by a small sample size and a single maker of the COVID-19 vaccine. Given the heterogeneity of vaccine accessibility across the world, future studies on other COVID-19 vaccines would be beneficial in informing public health decisions.

Click to read the study in The Lancet

Relevant Reading: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

In-depth [randomized controlled trial]: From Mar 11 to Mar 21, 2021, 90 patients were enrolled for a third ChAdOx1 nCoV-19 booster-dose in Oxford, UK. Additionally, of the 1110 patients who had received their first vaccination dose (previous studies), 321 were included in the analysis (267 with first and second-dose interval of 8-12 weeks, 24 with interval of 15-25 weeks, and 30 with an interval of 44-45 weeks) for comparison of delayed second-dose intervals. For each cohort, antibody titers were measured 28-days following the administration of a second or third vaccine. Included patients were those aged 18-55 years old with single or double doses of the ChAdOx1 nCoV-19 vaccination. The majority (>90%) of patients were White and median age, across cohort, ranged from 32-40 years old.

RELATED REPORTS

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

A prolonged interval between first and second doses was correlated with higher median antibody titers compared to a shorter interval (3738 EUs, interquartile range [IQR] 1824-6625] for 44-45 weeks vs. 1860 EUs [IQR 917-4934] for 15-25 weeks vs. 923 EUs [IQR 525-1764] for 8-12 weeks). A statistically significant difference was observed in IgG titers at 28 days after the third dose compared to 28-days after the second dose (3746 EUs, IQR 2047-6420 for third dose vs. 1792 EUs, IQR 899-4634, Wilcoxon signed rank test p=0.0043). Moreover, T-cell response also increased following the administration of a third dose (200 spot-forming units [SFUs] to 399 SFUs per million peripheral blood mononuclear cells [PBMCs], p=0.012). Findings from this study suggest that both an extended first to second dose interval and addition of a third dose provide increased immunogenicity against COVID-19.

Image: PD 

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: astrazenecaChAdOx1ChAdOx1 nCoV-19 vaccineChAdOx1 vaccinecovidcovid vaccineCOVID-19 antibodiesCOVID-19 VaccineSARS-CoV-2
Previous Post

Persistent human papillomavirus infection during pregnancy significantly associated with preterm birth

Next Post

Kuta Offers Many Hotspots for People with Alternative Lifestyles

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant
Infectious Disease

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

June 22, 2022
Waning Tdap vaccine effectiveness among adolescents
Infectious Disease

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

June 20, 2022
Social networks play key roles in parental vaccination decisions
Infectious Disease

Small-magnitude differences in risk of adverse events identified between the BNT162b2 and mRNA-1273 across 38 weeks follow-up

June 20, 2022
Next Post

Kuta Offers Many Hotspots for People with Alternative Lifestyles

#VisualAbstract: Melanoma survival outcomes have improved between 2003 and 2019 amidst increasing incidence rates

#VisualAbstract: Melanoma survival outcomes have improved between 2003 and 2019 amidst increasing incidence rates

High-flow oxygen therapy as effective as BiPAP in preventing reintubation

Probiotics not effective at reducing incidence of ventilator-associated pneumonia in critically ill patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.